Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
- DOI
- 10.1371/journal.pone.0118228
- Published
- 2015
- Container
- PloS one
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1371/journal.pone.0118228,
title = {Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.},
author = {Amin J and Boyd MA and Kumarasamy N and Moore CL and Losso MH and Nwizu CA and Mohapi L and Kerr SJ and Sohn AH and Teppler H and Renjifo B and Molina JM and Emery S and Cooper DA},
year = {2015},
journal = {PloS one},
doi = {10.1371/journal.pone.0118228},
url = {https://doi.org/10.1371/journal.pone.0118228}
}RIS
TY - JOUR TI - Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. AU - Amin J AU - Boyd MA AU - Kumarasamy N AU - Moore CL AU - Losso MH AU - Nwizu CA AU - Mohapi L AU - Kerr SJ AU - Sohn AH AU - Teppler H AU - Renjifo B AU - Molina JM AU - Emery S AU - Cooper DA PY - 2015 JO - PloS one DO - 10.1371/journal.pone.0118228 UR - https://doi.org/10.1371/journal.pone.0118228 ER -
APA
J, A., MA, B., N, K., CL, M., MH, L., CA, N., L, M., SJ, K., AH, S., H, T., B, R., JM, M., S, E., & DA, C. (2015). Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.. PloS one. https://doi.org/10.1371/journal.pone.0118228
Source records
- pubmed · retrieved 2026-09-26T11:24:20.984Z